1H-咪唑-2-甲醇盐酸盐 | 116177-22-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1H-咪唑-2-甲醇盐酸盐
• 英文名称: 2-(hydroxymethyl)imidazole hydrochloride
• 英文别名: 1H-imidazole-2-methanol hydrochloride；(1H-imidazol-2-yl)-methanol; hydrochloride；1H-imidazol-2-ylmethanol Hydrochloride；1H-imidazol-2-ylmethanol;hydrochloride
• CAS: 116177-22-1
• 化学式: C₄H₆N₂O*ClH
• 分子量: 134.565
• InChiKey: FEORNCWZOSTSRO-UHFFFAOYSA-N

物化性质

• 熔点：
  118-120

计算性质

• 辛醇/水分配系数(LogP)：
  0.32
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  48.9
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933290090
• 安全说明：
  S26,S37/39

SDS

Name:	1H-imidazol-2-ylmethanol hydrochloride 97% Material Safety Data Sheet
Synonym:
CAS:	116177-22-1

Section 1 - Chemical Product MSDS Name:1H-imidazol-2-ylmethanol hydrochloride 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
116177-22-1	1H-Imidazol-2-ylmethanol hydrochloride	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 116177-22-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 118 - 120 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H7ClN2O
Molecular Weight: 134.57

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 116177-22-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1H-Imidazol-2-ylmethanol hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 116177-22-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 116177-22-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 116177-22-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1H-咪唑-2-甲醇盐酸盐 在 氯化亚砜 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 生成 2-氯甲基-1h-咪唑盐酸盐
  参考文献：
  名称：

  Cholecystokinin antagonists

  摘要：

  公开了一种公式为##STR1##的苯二氮平类似物，它们是胃泌素和胆囊收缩素(CCK)的拮抗剂。

  公开号：

  US05218115A1

文献信息

• Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
  申请人：LG Chemical Ltd.

  公开号：US20020137769A1

  公开（公告）日：2002-09-26

  The present invention relates to novel imidazole derivatives which show an inhibitory activity against farnesyl transferase, pharmaceutically acceptable salts or isomers thereof and pharmaceutical compositions comprising such imidazole derivatives. More particularly, the present invention relates to intermediate compounds which are used in the preparation of the imidazole derivatives of the invention. Related processes also are disclosed.

  本发明涉及新型咪唑衍生物，其对法尼酰转移酶具有抑制活性，其药学上可接受的盐或异构体以及包含此类咪唑衍生物的制药组合物。更具体地说，本发明涉及用于制备本发明咪唑衍生物的中间化合物。相关的制备过程也被揭示。
• 6-Azaindole Compound
  申请人：Horiguchi Yoshiaki

  公开号：US20080064715A1

  公开（公告）日：2008-03-13

  A compound represented by the formula wherein R 1 , R 2 , R 3 and R 6 are the same or different and each is a hydrogen atom or a substituent; one of R 4 and R 5 is a hydrogen atom and the other is a group represented by the formula: —C(═X)—R 7 wherein X is N—O—R 8 or N—NH—R 9 wherein R 8 and R 9 are the same or different and each is a hydrogen atom or a group bonded via a carbon atom; and R 7 is a hydrogen atom or a substituent, and the like and a salt thereof have a superior IκB kinase inhibitory activity, and useful as pharmaceutical agents such as agents for preventing or treating diabetes and the like.

  一种化合物的化学式为其中R1、R2、R3和R6相同或不同，每个都是氢原子或取代基；R4和R5中的一个是氢原子，另一个是代表公式的基团：—C(═X)—R7，其中X为N—O—R8或N—NH—R9，R8和R9相同或不同，每个都是氢原子或通过碳原子键合的基团；而R7是氢原子或取代基等。该化合物及其盐具有优异的IκB激酶抑制活性，并可用作预防或治疗糖尿病等药物。
• Hydantoin compounds and methods related thereto
  申请人：LG Chemical Ltd.

  公开号：US06384061B1

  公开（公告）日：2002-05-07

  The present invention relates to novel hydantoin compounds represented by formula (I) which shows an inhibitory activity against farnesyl transferase, and thus can be used as an anti-cancer agent, or pharmaceutically acceptable salts thereof, in which R1, R2, R3 and R4 are as defined in the present application. The present invention also relates to a process for preparation of the compound of formula (I), and to an anti-cancer composition comprising the compound of formula (I) as an active ingredient.

  本发明涉及一种新型的咪唑二酮化合物，其化学式为(I)，该化合物具有对法尼酰基转移酶的抑制活性，因此可以用作抗癌剂或其药学上可接受的盐，其中R1、R2、R3和R4如本申请所定义。本发明还涉及一种制备化合物(I)的方法，以及一种包含化合物(I)作为活性成分的抗癌组合物。
• 6-azaindole compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07608627B2

  公开（公告）日：2009-10-27

  A compound represented by the formula wherein R1, R2, R3 and R6 are the same or different and each is a hydrogen atom or a substituent; one of R4 and R5 is a hydrogen atom and the other is a group represented by the formula: —C(═X)—R7 wherein X is N—O—R8 or N—NH—R9 wherein R8 and R9 are the same or different and each is a hydrogen atom or a group bonded via a carbon atom; and R7 is a hydrogen atom or a substituent, and the like and a salt thereof have a superior IκB kinase inhibitory activity, and useful as pharmaceutical agents such as agents for preventing or treating diabetes and the like.

  该化合物的化学式表示为其中R1，R2，R3和R6相同或不同，每个都是氢原子或取代基; R4和R5中的一个是氢原子，另一个是表示为公式的基团：—C（═X）—R7，其中X为N—O—R8或N—NH—R9，其中R8和R9相同或不同，每个都是氢原子或通过碳原子连接的基团; R7是氢原子或取代基，类似物及其盐具有优良的IκB激酶抑制活性，并可用作预防或治疗糖尿病等药物。
• WO2007/70433
  申请人：——

  公开号：——

  公开（公告）日：——